Sakai H et al. |
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
2018 |
Breast Cancer |
pmid:29700710
|
Higa GM |
The microtubule as a breast cancer target. |
2011 |
Breast Cancer |
pmid:20862571
|
Montemurro F |
HER2 expression and efficacy of T-DM1. |
2014 |
Breast Cancer Res. |
pmid:25472666
|
Perez EA et al. |
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. |
2014 |
Breast Cancer Res. |
pmid:24887458
|
Barok M et al. |
Trastuzumab emtansine: mechanisms of action and drug resistance. |
2014 |
Breast Cancer Res. |
pmid:24887180
|
Barok M et al. |
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. |
2011 |
Breast Cancer Res. |
pmid:21510863
|
Baldassarre T et al. |
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. |
2017 |
Breast Cancer Res. |
pmid:28974266
|
Krop IE et al. |
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. |
2016 |
Breast Cancer Res. |
pmid:26979312
|
Diaby V et al. |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. |
2017 |
Breast Cancer Res. Treat. |
pmid:28840424
|
Le QA et al. |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. |
2016 |
Breast Cancer Res. Treat. |
pmid:27572338
|
Jacot W et al. |
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. |
2016 |
Breast Cancer Res. Treat. |
pmid:27167986
|
Junttila TT et al. |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. |
2011 |
Breast Cancer Res. Treat. |
pmid:20730488
|
Sibaud V et al. |
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. |
2014 |
Breast Cancer Res. Treat. |
pmid:24929675
|
Tanz R et al. |
[Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. |
2014 Jul-Aug |
Bull Cancer |
pmid:25091656
|
Gonçalves A et al. |
[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. |
2012 |
Bull Cancer |
pmid:23247898
|
Frenel JS et al. |
[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. |
2016 |
Bull Cancer |
pmid:26992855
|
Monneret C and Florent JC |
[Targeting of antitumor drugs with monoclonal antibodies]. |
2000 |
Bull Cancer |
pmid:11125291
|
Guerin M et al. |
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. |
2015 |
Bull Cancer |
pmid:25790739
|
Luduena RF et al. |
N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. |
1985 |
Can. J. Biochem. Cell Biol. |
pmid:4041960
|
Schibler MJ and Cabral FR |
Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. |
1985 |
Can. J. Biochem. Cell Biol. |
pmid:4041962
|